Posted by Michael Wonder on 15 Jun 2021
GBT’s voxelotor is first sickle cell disease treatment to receive promising innovative medicine designation in the UK
14 June 2021 - Global Blood Therapeutics announced today that the MHRA in the United Kingdom has granted a Promising Innovative Medicine designation for voxelotor for the potential treatment of haemolytic anaemia in adults and adolescent patients 12 years of age and older with sickle cell disease.
A first-in-class oral, once-daily therapy, voxelotor directly inhibits hemoglobin S polymerisation, the root cause of the sickling and destruction of red blood cells in sickle cell disease.
